Using  ||| S:0 E:6 ||| VBG
Human  ||| S:6 E:12 ||| NNP
Induced  ||| S:12 E:20 ||| NNP
Pluripotent  ||| S:20 E:32 ||| NNP
Stem  ||| S:32 E:37 ||| NNP
Cells  ||| S:37 E:43 ||| NNP
to  ||| S:43 E:46 ||| TO
Model  ||| S:46 E:52 ||| NNP
Skeletal  ||| S:52 E:61 ||| NNP
Diseases  ||| S:61 E:70 ||| NNP
Musculoskeletal  ||| S:70 E:86 ||| NNP
disorders  ||| S:86 E:96 ||| NNS
affecting  ||| S:96 E:106 ||| VBG
the  ||| S:106 E:110 ||| DT
bones  ||| S:110 E:116 ||| NNS
and  ||| S:116 E:120 ||| CC
joints  ||| S:120 E:127 ||| NNS
are  ||| S:127 E:131 ||| VBP
major  ||| S:131 E:137 ||| JJ
health  ||| S:137 E:144 ||| NN
problems  ||| S:144 E:153 ||| NNS
among  ||| S:153 E:159 ||| IN
children  ||| S:159 E:168 ||| NNS
and  ||| S:168 E:172 ||| CC
adults ||| S:172 E:178 ||| NNS
.  ||| S:178 E:180 ||| .
Major  ||| S:180 E:186 ||| JJ
challenges  ||| S:186 E:197 ||| NNS
such  ||| S:197 E:202 ||| JJ
as  ||| S:202 E:205 ||| IN
the  ||| S:205 E:209 ||| DT
genetic  ||| S:209 E:217 ||| JJ
origins  ||| S:217 E:225 ||| NNS
or  ||| S:225 E:228 ||| CC
poor  ||| S:228 E:233 ||| JJ
diagnostics  ||| S:233 E:245 ||| NNS
of  ||| S:245 E:248 ||| IN
severe  ||| S:248 E:255 ||| JJ
skeletal  ||| S:255 E:264 ||| JJ
disease  ||| S:264 E:272 ||| NN
hinder  ||| S:272 E:279 ||| VB
our  ||| S:279 E:283 ||| PRP$
understanding  ||| S:283 E:297 ||| NN
of  ||| S:297 E:300 ||| IN
human  ||| S:300 E:306 ||| JJ
skeletal  ||| S:306 E:315 ||| JJ
diseases ||| S:315 E:323 ||| NNS
.  ||| S:323 E:325 ||| .
The  ||| S:325 E:329 ||| DT
recent  ||| S:329 E:336 ||| JJ
advent  ||| S:336 E:343 ||| NN
of  ||| S:343 E:346 ||| IN
human  ||| S:346 E:352 ||| JJ
induced  ||| S:352 E:360 ||| JJ
pluripotent  ||| S:360 E:372 ||| NNS
stem  ||| S:372 E:377 ||| VBP
cells  ||| S:377 E:383 ||| NNS
( ||| S:383 E:384 ||| -LRB-
human  ||| S:384 E:390 ||| JJ
iPS  ||| S:390 E:394 ||| JJ
cells ||| S:394 E:399 ||| NNS
)  ||| S:399 E:401 ||| -RRB-
provides  ||| S:401 E:410 ||| VBZ
an  ||| S:410 E:413 ||| DT
unparalleled  ||| S:413 E:426 ||| JJ
opportunity  ||| S:426 E:438 ||| NN
to  ||| S:438 E:441 ||| TO
create  ||| S:441 E:448 ||| VB
human-specific  ||| S:448 E:463 ||| JJ
models  ||| S:463 E:470 ||| NNS
of  ||| S:470 E:473 ||| IN
human  ||| S:473 E:479 ||| JJ
skeletal  ||| S:479 E:488 ||| NNS
diseases.  ||| S:488 E:498 ||| VBP
iPS  ||| S:498 E:502 ||| JJ
cells  ||| S:502 E:508 ||| NNS
have  ||| S:508 E:513 ||| VBP
the  ||| S:513 E:517 ||| DT
ability  ||| S:517 E:525 ||| NN
to  ||| S:525 E:528 ||| TO
self-renew ||| S:528 E:538 ||| JJ
,  ||| S:538 E:540 ||| ,
allowing  ||| S:540 E:549 ||| VBG
us  ||| S:549 E:552 ||| PRP
to  ||| S:552 E:555 ||| TO
obtain  ||| S:555 E:562 ||| VB
large  ||| S:562 E:568 ||| JJ
amounts  ||| S:568 E:576 ||| NNS
of  ||| S:576 E:579 ||| IN
starting  ||| S:579 E:588 ||| VBG
material ||| S:588 E:596 ||| NN
,  ||| S:596 E:598 ||| ,
and  ||| S:598 E:602 ||| CC
have  ||| S:602 E:607 ||| VB
the  ||| S:607 E:611 ||| DT
potential  ||| S:611 E:621 ||| JJ
to  ||| S:621 E:624 ||| TO
differentiate  ||| S:624 E:638 ||| VB
into  ||| S:638 E:643 ||| IN
any  ||| S:643 E:647 ||| DT
cell  ||| S:647 E:652 ||| NN
types  ||| S:652 E:658 ||| NNS
in  ||| S:658 E:661 ||| IN
the  ||| S:661 E:665 ||| DT
body ||| S:665 E:669 ||| NN
.  ||| S:669 E:671 ||| .
In  ||| S:671 E:674 ||| IN
addition ||| S:674 E:682 ||| NN
,  ||| S:682 E:684 ||| ,
they  ||| S:684 E:689 ||| PRP
can  ||| S:689 E:693 ||| MD
carry  ||| S:693 E:699 ||| VB
one  ||| S:699 E:703 ||| CD
or  ||| S:703 E:706 ||| CC
more  ||| S:706 E:711 ||| RBR
mutations  ||| S:711 E:721 ||| JJ
responsible  ||| S:721 E:733 ||| JJ
for  ||| S:733 E:737 ||| IN
the  ||| S:737 E:741 ||| DT
disease  ||| S:741 E:749 ||| NN
of  ||| S:749 E:752 ||| IN
interest  ||| S:752 E:761 ||| NN
or  ||| S:761 E:764 ||| CC
be  ||| S:764 E:767 ||| VB
genetically  ||| S:767 E:779 ||| RB
corrected  ||| S:779 E:789 ||| VBN
to  ||| S:789 E:792 ||| TO
create  ||| S:792 E:799 ||| VB
isogenic  ||| S:799 E:808 ||| JJ
controls ||| S:808 E:816 ||| NNS
.  ||| S:816 E:818 ||| .
Our  ||| S:818 E:822 ||| PRP$
work  ||| S:822 E:827 ||| NN
has  ||| S:827 E:831 ||| VBZ
focused  ||| S:831 E:839 ||| VBN
on  ||| S:839 E:842 ||| IN
modeling  ||| S:842 E:851 ||| FW
rare  ||| S:851 E:856 ||| FW
musculoskeletal  ||| S:856 E:872 ||| FW
disorders  ||| S:872 E:882 ||| FW
including  ||| S:882 E:892 ||| FW
fibrodysplasia  ||| S:892 E:907 ||| FW
ossificans  ||| S:907 E:918 ||| FW
progressive  ||| S:918 E:930 ||| FW
( ||| S:930 E:931 ||| -LRB-
FOP ||| S:931 E:934 ||| NNP
) ||| S:934 E:935 ||| -RRB-
,  ||| S:935 E:937 ||| ,
a  ||| S:937 E:939 ||| DT
congenital  ||| S:939 E:950 ||| JJ
disease  ||| S:950 E:958 ||| NN
of  ||| S:958 E:961 ||| IN
increased  ||| S:961 E:971 ||| JJ
heterotopic  ||| S:971 E:983 ||| JJ
ossification ||| S:983 E:995 ||| NN
.  ||| S:995 E:997 ||| .
In  ||| S:997 E:1000 ||| IN
this  ||| S:1000 E:1005 ||| DT
review ||| S:1005 E:1011 ||| NN
,  ||| S:1011 E:1013 ||| ,
we  ||| S:1013 E:1016 ||| PRP
will  ||| S:1016 E:1021 ||| MD
discuss  ||| S:1021 E:1029 ||| VB
our  ||| S:1029 E:1033 ||| PRP$
experiences  ||| S:1033 E:1045 ||| NNS
and  ||| S:1045 E:1049 ||| CC
protocols  ||| S:1049 E:1059 ||| NNS
differentiating  ||| S:1059 E:1075 ||| VBG
human  ||| S:1075 E:1081 ||| JJ
iPS  ||| S:1081 E:1085 ||| JJ
cells  ||| S:1085 E:1091 ||| NNS
toward  ||| S:1091 E:1098 ||| IN
the  ||| S:1098 E:1102 ||| DT
osteogenic  ||| S:1102 E:1113 ||| JJ
lineage  ||| S:1113 E:1121 ||| NN
and  ||| S:1121 E:1125 ||| CC
their  ||| S:1125 E:1131 ||| PRP$
application  ||| S:1131 E:1143 ||| NN
to  ||| S:1143 E:1146 ||| TO
model  ||| S:1146 E:1152 ||| VB
skeletal  ||| S:1152 E:1161 ||| JJ
diseases ||| S:1161 E:1169 ||| NNS
.  ||| S:1169 E:1171 ||| .
A  ||| S:1171 E:1173 ||| DT
number  ||| S:1173 E:1180 ||| NN
of  ||| S:1180 E:1183 ||| IN
critical  ||| S:1183 E:1192 ||| JJ
challenges  ||| S:1192 E:1203 ||| NNS
and  ||| S:1203 E:1207 ||| CC
exciting  ||| S:1207 E:1216 ||| JJ
new  ||| S:1216 E:1220 ||| JJ
approaches  ||| S:1220 E:1231 ||| NNS
are  ||| S:1231 E:1235 ||| VBP
also  ||| S:1235 E:1240 ||| RB
discussed ||| S:1240 E:1249 ||| VBN
,  ||| S:1249 E:1251 ||| ,
which  ||| S:1251 E:1257 ||| WDT
will  ||| S:1257 E:1262 ||| MD
allow  ||| S:1262 E:1268 ||| VB
the  ||| S:1268 E:1272 ||| DT
skeletal  ||| S:1272 E:1281 ||| JJ
biology  ||| S:1281 E:1289 ||| NN
field  ||| S:1289 E:1295 ||| NN
to  ||| S:1295 E:1298 ||| TO
harness  ||| S:1298 E:1306 ||| VB
the  ||| S:1306 E:1310 ||| DT
potential  ||| S:1310 E:1320 ||| NN
of  ||| S:1320 E:1323 ||| IN
human  ||| S:1323 E:1329 ||| JJ
iPS  ||| S:1329 E:1333 ||| JJ
cells  ||| S:1333 E:1339 ||| NNS
as  ||| S:1339 E:1342 ||| IN
a  ||| S:1342 E:1344 ||| DT
critical  ||| S:1344 E:1353 ||| JJ
model  ||| S:1353 E:1359 ||| NN
system  ||| S:1359 E:1366 ||| NN
for  ||| S:1366 E:1370 ||| IN
understanding  ||| S:1370 E:1384 ||| VBG
diseases  ||| S:1384 E:1393 ||| NNS
of  ||| S:1393 E:1396 ||| IN
abnormal  ||| S:1396 E:1405 ||| JJ
skeletal  ||| S:1405 E:1414 ||| JJ
formation  ||| S:1414 E:1424 ||| NN
and  ||| S:1424 E:1428 ||| CC
bone  ||| S:1428 E:1433 ||| NN
regeneration ||| S:1433 E:1445 ||| NN
.  ||| S:1445 E:1447 ||| .
